An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

A Pennsylvania federal district court denied summary judgment to Gilead Sciences, Inc. on the wrongful discharge claim under state law of an employed at-will therapeutic specialist who sold its ...

Gilead Sciences, Inc. (NASDAQ ... and median overall survival was not yet reached. In summary, we are encouraged by the compelling results so far, and with over 140 patients dosed across both the ...

Scottish Medicines Consortium Accepts Kite CAR T-Cell Therapy for Earlier Use to Treat Aggressive Blood Cancers - First SMC acceptance of any CAR T-cell therapy for lymphoma patients in the ...

Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with ...

Global Regenerative Medicine Market is valued at approximately USD 34.56 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 32.4% over the forecast period 2024-2032.

Summary of Assay Results for Hole BRG24-255 and 256 1 ... Inc. ("Metagenomi" or the "Company") of a class action securities lawsuit.... Gilead Sciences, Inc. today announced the presentation of new ...

As Modern Healthcare reports, CMS has relaxed supervision requirements for physical and occupational therapist assistants from “direct” to “general.” The change could help health systems manage ...